Viral myocarditis-diagnosis, treatment options, and current controversies

Nature Reviews Cardiology

Volumn 12, Issue 11, 2015, Pages 670-680

  Pollack, Ari ^a   Kontorovich, Amy R ^a   Fuster, Valentin ^a   Dec, G William ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRAL THERAPY; CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; EVIDENCE BASED PRACTICE; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; MEDICAL HISTORY; MULTICENTER STUDY (TOPIC); NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VIRUS MYOCARDITIS; MYOCARDITIS; VIROLOGY; VIRUS DISEASES;

ANTIVIRUS AGENT;

ANTIVIRAL AGENTS; HUMANS; MYOCARDITIS; VIRUS DISEASES;

EID: 84945477620     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2015.108     Document Type: Review

References (98)

1. Caforio, A. L., et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 34, 2636-2648 (2013
2. Richardson, P., et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 93, 841-842 (1996
3. Breinholt, J. P., et al. Viral epidemiologic shift in inflammatory heart disease: the increasing involvement of parvovirus B19 in the myocardium of pediatric cardiac transplant patients. J. Heart Lung Transplant. 29, 739-746 (2010
4. Schultz, J. C., Hilliard, A. A., Cooper, L. T Jr., & Rihal, C. S. Diagnosis and treatment of viral myocarditis. Mayo Clin. Proc. 84, 1001-1009 (2009
5. Magnani, J. W., & Dec, G. W. Myocarditis: current trends in diagnosis and treatment. Circulation. 113, 876-890 (2006
6. Towbin, J. A., et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. 296, 1867-1876 (2006
7. Doolan, A., Langlois, N., & Semsarian, C. Causes of sudden cardiac death in young Australians. Med. J. Aust. 180, 110-112 (2004
8. Fabre, A., & Sheppard, M. N. Sudden adult death syndrome and other non-ischaemic causes of sudden cardiac death. Heart. 92, 316-320 (2006
9. Felker, G. M., et al. The spectrum of dilated cardiomyopathy. The Johns Hopkins experience with. 1,278 patients. Medicine (Baltimore) 78, 270-283 (1999
10. Maron, B. J., et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 113, 1807-1816 (2006
11. Aretz, H. T., et al. Myocarditis. A histopathologic definition and classification. Am. J. Cardiovasc. Pathol. 1, 3-14 (1987
12. Baughman, K. L. Diagnosis of myocarditis: death of Dallas criteria. Circulation. 113, 593-595 (2006
13. Wu, L. A., Lapeyre, A. C. 3rd., & Cooper, L. T. Current role of endomyocardial biopsy in the management of dilated cardiomyopathy and myocarditis. Mayo Clin. Proc. 76, 1030-1038 (2001
14. Hauck, A. J., Kearney, D. L., & Edwards, W. D. Evaluation of postmortem endomyocardial biopsy specimens from. 38 patients with lymphocytic myocarditis: implications for role of sampling error. Mayo Clin. Proc. 64, 1235-1245 (1989
15. Kindermann, I., et al. Update on myocarditis. J. Am. Coll. Cardiol. 59, 779-792 (2012
16. Fairley, C. K., Ryan, M., Wall, P. G., & Weinberg, J. The organisms reported to cause infective myocarditis and pericarditis in England and Wales. J. Infect. 32, 223-225 (1996
17. Kawai, C. Idiopathic cardiomyopathy. A study on the infectious-immune theory as a cause of the disease. Jpn. Circ. J. 35, 765-770 (1971
18. Freimuth, P., Philipson, L., & Carson, SD. The coxsackievirus and adenovirus receptor. Curr. Top. Microbiol. Immunol. 323, 67-87 (2008
19. Pinkert, S., et al. Prevention of cardiac dysfunction in acute coxsackievirus B3 cardiomyopathy by inducible expression of a soluble coxsackievirus-Adenovirus receptor. Circulation. 120, 2358-2366 (2009
20. Blailock, Z. R., Rabin, E. R., & Melnick, J. L. Adenovirus myocarditis in mice. An electron microscopic study. Exp. Mol. Pathol. 9, 84-96 (1968
21. Shi, Y., et al. Cardiac deletion of the coxsackievirus-Adenovirus receptor abolishes coxsackievirus B3 infection and prevents myocarditis in vivo. J. Am. Coll. Cardiol. 53, 1219-1226 (2009
22. Kandolf, R., Ameis, D., Kirschner, P., Canu, A., & Hofschneider, P. H. In situ detection of enteroviral genomes in myocardial cells by nucleic acid hybridization: an approach to the diagnosis of viral heart disease. Proc. Natl Acad. Sci. USA. 84, 6272-6276 (1987
23. Badorff, C., et al. Enteroviral protease. 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat. Med. 5, 320-326 (1999
24. Bültmann, B. D., et al. Fatal parvovirus B19-Associated myocarditis clinically mimicking ischemic heart disease: an endothelial cell-mediated disease. Hum. Pathol. 34, 92-95 (2003
25. Bock, C. T., Klingel, K., & Kandolf, R. Human parvovirus B19-Associated myocarditis. N. Engl. J. Med. 362, 1248-1249 (2010
26. Kühl, U., et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with idiopathic left ventricular dysfunction. Circulation. 111, 887-893 (2005
27. Kühl, U., et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation. 112, 1965-1970 (2005
28. Caforio, A. L., et al. A prospective study of biopsy proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur. Heart J. 28, 1326-1333 (2007
29. Mason, J. W., et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N. Engl. J. Med. 333, 269-275 (1995
30. Smith, S. C., Ladenson, J. H., Mason, J. W., & Jaffe, A. S. Elevations of cardiac troponin I associated with myocarditis. Experimental and clinical correlates. Circulation. 95, 163-168 (1997
31. Mahfoud, F., et al. Virus serology in patients with suspected myocarditis: utility or futility?. Eur. Heart J. 32, 897-903 (2011
32. Dec, G. W Jr., et al. Viral myocarditis mimicking acute myocardial infarction. J. Am. Coll. Cardiol. 20, 85-89 (1992
33. Angelini, A., et al. Myocarditis mimicking acute myocardial infarction: role of endomyocardial biopsy in the differential diagnosis. Heart. 84, 245-250 (2000
34. Friedrich, M. G., et al. Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation. 97, 1802-1809 (1998
35. Felker, G. M., et al. Echocardiographic findings in fulminant and acute myocarditis. J. Am. Coll. Cardiol. 36, 227-232 (2000
36. Herskowitz, A., et al. Demographic features and prevalence of idiopathic myocarditis in patients undergoing endomyocardial biopsy. Am. J. Cardiol. 71, 982-986 (1993
37. Kindermann, I., et al. Predictors of outcome in patients with suspected myocarditis. Circulation. 118, 639-648 (2008
38. McCarthy, R. E. 3rd et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N. Engl. J. Med. 342, 690-695 (2000
39. Anzini, M., et al. Long-term evolution and prognostic stratification of biopsy-proven active myocarditis. Circulation. 128, 2384-2394 (2013
40. Cooper, L. T Jr, Berry, G. J., & Shabetai, R. Idiopathic giant-cell myocarditis-natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N. Engl. J. Med. 336, 1860-1866 (1997
41. Yilmaz, A., et al. Role of cardiovascular magnetic resonance imaging (CMR) in the diagnosis of acute and chronic myocarditis. Heart Fail. Rev. 18, 747-760 (2013
42. Friedrich, M. G., et al. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J. Am. Coll. Cardiol. 53, 1475-1487 (2009
43. Abdel-Aty, H., et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J. Am. Coll. Cardiol. 45, 1815-1822 (2005
44. Mahrholdt, H., et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation. 114, 1581-1590 (2006
45. Grün, S., et al. Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J. Am. Coll. Cardiol. 59, 1604-1615 (2012
46. Baccouche, H., et al. Diagnostic synergy of non-invasive cardiovascular magnetic resonance and invasive endomyocardial biopsy in troponin-positive patients without coronary artery disease. Eur. Heart J. 30, 2869-2879 (2009
47. Gutberlet, M., et al. Suspected chronic myocarditis at cardiac MR: diagnostic accuracy and association with immunohistologically detected inflammation and viral persistence. Radiology. 246, 401-409 (2008
48. Cooper, L. T., et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J. Am. Coll. Cardiol. 50, 1914-1931 (2007
49. Jacoby, C., et al. Visualization of immune cell infiltration in experimental viral myocarditis by. 19F MRI in vivo. MAGMA. 27, 101-106 (2014
50. Bates, D., Abraham, S., Campbell, M., Zehbe, I., & Curiel, L. Development and characterization of an antibody-labeled super-paramagnetic iron oxide contrast agent targeting prostate cancer cells for magnetic resonance imaging. PLoS ONE. 9, e97220 (2014
51. Shahbazi-Gahrouei, D., Williams, M., Rizvi, S., & Allen, B. J. In vivo studies of Gd DTPA-monoclonal antibody and gd-porphyrins: potential magnetic resonance imaging contrast agents for melanoma. J. Magn. Reson. Imaging. 14, 169-174 (2001
52. Jamar, F., et al. EANM/SNMMI guideline for. 18F FDG use in inflammation and infection. J. Nucl. Med. 54, 647-658 (2013
53. Ohira, H., et al. Myocardial imaging with. 18F fluoro. 2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur. J. Nucl. Med. Mol. Imaging. 35, 933-941 (2008
54. Brudin, L. H., et al. Fluorine. 18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur. J. Nucl. Med. 21, 297-305 (1994
55. Blankstein, R., et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J. Am. Coll. Cardiol. 63, 329-336 (2014
56. Klingel, K., et al. Pathogenesis of murine enterovirus myocarditis: virus dissemination and immune cell targets. J. Virol. 70, 8888-8895 (1996
57. Calabrese, F., & Thiene, G. Myocarditis and inflammatory cardiomyopathy: microbiological and molecular biological aspects. Cardiovasc. Res. 60, 11-25 (2003
58. Dennert, R., Crijns, H. J., & Heymans, S. Acute viral myocarditis. Eur. Heart J. 29, 2073-2082 (2008
59. Why, H. J., et al. Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy. Circulation. 89, 2582-2589 (1994
60. Leone, O., et al. 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc. Pathol. 21, 245-274 (2012
61. Holzmann, M., et al. Complication rate of right ventricular endomyocardial biopsy via the femoral approach: a retrospective and prospective study analyzing. 3048 diagnostic procedures over an. 11-year period. Circulation. 118, 1722-1728 (2008
62. Yilmaz, A., et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation. 122, 900-909 (2010
63. Chimenti, C., & Frustaci, A. Contribution and risks of left ventricular endomyocardial biopsy in patients with cardiomyopathies: a retrospective study over a. 28-year period. Circulation. 128, 1531-1541 (2013
64. Mahrholdt, H., et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation. 109, 1250-1258 (2004
65. Feldman, A. M., & McNamara, D. Myocarditis. N. Engl. J. Med. 343, 1388-1398 (2000
66. Costanzo-Nordin, M. R., Reap, E. A., OConnell, J. B., Robinson, J. A., & Scanlon, P. J. A nonsteroid anti-inflammatory drug exacerbates Coxsackie B3 murine myocarditis. J. Am. Coll. Cardiol. 6, 1078-1082 (1985
67. Hobbs, R. E., et al. Lymphocytic myocarditis and dilated cardiomyopathy: treatment with immunosuppressive agents. Cleve. Clin. J. Med. 56, 628-635 (1989
68. Parrillo, J. E., et al. A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N. Engl. J. Med. 321, 1061-1068 (1989
69. Wojnicz, R., et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation. 104, 39-45 (2001
70. Frustaci, A., Russo, M. A., & Chimenti, C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur. Heart J. 30, 1995-2002 (2009
71. Pulerwitz, T. C., et al. Mortality in primary and secondary myocarditis. Am. Heart J. 147, 746-750 (2004
72. Orange, J. S., et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J. Allergy Clin. Immunol. 117, S525-S553 (2006
73. Menghini, V. V., et al. Combined immunosuppression for the treatment of idiopathic giant cell myocarditis. Mayo Clin. Proc. 74, 1221-1226 (1999
74. McNamara, D. M., et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 103, 2254-2259 (2001
75. Gullestad, L., et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation. 103, 220-225 (2001
76. Drucker, N. A., et al. γ globulin treatment of acute myocarditis in the pediatric population. Circulation 89 252-257 1994
77. Felix, S. B., et al. Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J. Am. Coll. Cardiol. 39, 646-652 (2002
78. Bygren, P., et al. Goodpastures syndrome treated with staphylococcal protein A immunoadsorption. Lancet. 2, 1295-1296 (1985
79. Palmer, A., Gjorstrup, P., Severn, A., Welsh, K., & Taube, D. Treatment of systemic lupus erythematosus by extracorporeal immunoadsorption. Lancet. 2, 272 (1988
80. Mobini, R., et al. Hemodynamic improvement and removal of autoantibodies against β1-Adrenergic receptor by immunoadsorption therapy in dilated cardiomyopathy. J. Autoimmun. 20, 345-350 (2003
81. Herda, L. R., et al. Effects of immunoadsorption and subsequent immunoglobulin G substitution on cardiopulmonary exercise capacity in patients with dilated cardiomyopathy. Am. Heart J. 159, 809-816 (2010
82. Felix, S. B., et al. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J. Am. Coll. Cardiol. 35, 1590-1598 (2000
83. Doesch, A. O., et al. Effects of protein A immunoadsorption in patients with advanced chronic dilated cardiomyopathy. J. Clin. Apher. 24, 141-149 (2009
84. US National Library of Medicine ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00558584 (2015
85. Mann, D. L., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 109, 1594-1602 (2004
86. Chung, E. S., Packer, M., Lo, K. H., Fasanmade, A. A., & Willerson, J. T. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor α, in patients with moderate to severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 107, 3133-3140 (2003
87. Krueger, G. R., & Ablashi, D. V. Human herpesvirus. 6: a short review of its biological behavior. Intervirology. 46, 257-269 (2003
88. Martino, T. A., Liu, P., & Sole, M. J. Viral infection and the pathogenesis of dilated cardiomyopathy. Circ. Res. 74, 182-188 (1994
89. Wang, Y. X., et al. Antiviral and myocyte protective effects of murine interferon β and α2 in coxsackievirus B3-induced myocarditis and epicarditis in Balb/c mice. Am J. Physiol. Heart Circ. Physiol. 293, H69-H76 (2007
90. Kühl, U., et al. Interferon β treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation. 107, 2793-2798 (2003
91. Schultheiss, H., et al. The effect of subcutaneous treatment with interferon β-1b over. 24 weeks on safety, virus elimination and clinical outcome in patients with chronic viral cardiomyopathy [abstract]. Circulation. 118, 3322 (2008
92. Carvajal-Vergara, X., et al. Patient-specific induced pluripotent stem cell derived models of LEOPARD syndrome. Nature. 465, 808-812 (2010
93. Sharma, A., et al. Human induced pluripotent stem cell-derived cardiomyocytes as an in vitro model for coxsackievirus B3-induced myocarditis and antiviral drug screening platform. Circ. Res. 115, 556-566 (2014
94. Maisch, B., Berg, P. A., & Kochsiek, K. Autoantibodies and serum inhibition factors (sif) in patients with myocarditis. Klin. Wochenschr. 58, 219-225 (1980
95. Maisch, B., Trostel-Soeder, R., Stechemesser, E., Berg, P. A., & Kochsiek, K. Diagnostic relevance of humoral and cell-mediated immune reactions in patients with acute viral myocarditis. Clin. Exp. Immunol. 48, 533-545 (1982
96. Minor, P. in Topley and Wilsons Microbiology and Microbial Infections. 9th edn Vol. 1 Ch. 25 (eds Mahy, B. W. J., & Collier, L.) 485-510 (Oxford University Press, 1998
97. Kim, K. S., Hufnagel, G., Chapman, N. M., & Tracy, S. The group B coxsackieviruses and myocarditis. Rev. Med. Virol. 11, 355-368 (2001
98. Szalay, G., et al. Osteopontin: a fibrosis-related marker molecule in cardiac remodeling of enterovirus myocarditis in the susceptible host. Circ. Res. 104, 851-859 (2009